status post left hemicolectomy for descending colon adenocarcinoma with bilateral ovarian metastasis what is prognosis?
Reading File
Finding Sources
Finding Sources
Searching PubMed
ovarian metastasis colorectal cancer prognosis survival
Searching the Web
bilateral ovarian metastasis colorectal adenocarcinoma prognosis survival oophorectomy 2024 2025
Reading Article
PMID: 37355393
Searching PubMed
ovarian metastasis colorectal cancer oophorectomy survival outcomes
Finding Sources
Reading Web Page
https://cinj.org/sites/cinj/files/documents/Epidemiology%20a…
Reading Article
PMID: 32591962
Reading Article
PMID: 40071236
Finding Sources
I now have robust data from the meta-analysis and multiple studies to provide a thorough answer.
Prognosis: Descending Colon Adenocarcinoma s/p Left Hemicolectomy with Bilateral Ovarian Metastasis
This is a stage IV (M1b) colorectal cancer - the bilateral ovarian involvement constitutes distant metastatic disease. The prognosis is generally poor but is significantly modifiable by surgical and systemic treatment decisions. Here is a detailed breakdown:
Overall Prognosis
- Median overall survival (OS) without surgical intervention: approximately 10-12 months
- With optimal management (R0 oophorectomy + systemic chemotherapy): median OS can extend to 19-30+ months in selected patients
- The bilateral nature is an independent adverse prognostic factor (HR 1.66, 95% CI: 1.09-2.51) compared to unilateral ovarian metastasis, per the 2023 meta-analysis by Shi et al. (PMID 37355393, 997 patients across 15 studies)
Key Prognostic Factors
Adverse Factors
| Factor | Prognostic Impact |
|---|---|
| Bilateral ovarian metastasis | HR 1.66 for shorter OS (vs. unilateral) |
| Extra-ovarian/peritoneal metastases | HR 3.00 for shorter OS |
| Incomplete cytoreduction (R1/R2) | Strongest independent predictor of poor survival |
| KRAS/BRAF mutation | Associated with worse outcomes; KRAS-mutant patients have more aggressive disease |
| Synchronous presentation (at time of primary diagnosis) | More common with colon cancer; reflects higher tumor burden |
| Elevated CA-125 | Present in ~67% of cases; correlates with peritoneal spread |
Favorable Factors
| Factor | Prognostic Benefit |
|---|---|
| R0 resection (complete cytoreduction) | HR 0.26 - most powerful positive predictor; independent determinant of survival |
| Ovarian metastasectomy | HR 0.44 for OS (Shi et al. meta-analysis) |
| Systemic chemotherapy | HR 0.26 for disease-specific survival |
| Age <50 / premenopausal | More likely to have isolated OM; better surgical candidates |
Specific Survival Data
- Chemotherapy alone: median OS ~10.3 months (Alawabdeh et al., 2025, PMID 40071236)
- Palliative oophorectomy + chemotherapy: median OS ~19.3 months (same study, P=0.05)
- KRAS-mutant + oophorectomy: median OS ~29.1 months vs. 10.3 months with chemotherapy alone (P=0.03)
- Overall median survival across all CROM patients: ~12 months (Zhou et al., 2020, PMID 32591962, n=46)
- R0 cytoreduction was the only independent determinant of survival by multivariate analysis (HR 0.186, 95% CI: 0.047-0.727)
Classification Note: Krukenberg vs. Direct Spread
Bilateral ovarian metastasis from colorectal cancer can represent:
- Krukenberg tumor - signet-ring cell mucin-secreting type (hematogenous/lymphatic spread; worse prognosis)
- Transcoelomic/peritoneal seeding - often associated with peritoneal carcinomatosis (very poor prognosis)
- Direct contiguous spread (less common from descending colon)
The histological subtype of ovarian involvement influences prognosis - signet ring / mucinous type carries a particularly dismal course.
Treatment Implications for Prognosis
- Surgical resection (oophorectomy achieving R0) - the single most impactful intervention; should be pursued aggressively if no unresectable extra-ovarian disease
- Systemic chemotherapy (FOLFOX/FOLFIRI ± bevacizumab or anti-EGFR depending on RAS/BRAF status) - mandatory; improves disease-specific survival
- Molecular profiling (KRAS, NRAS, BRAF, MSI/MMR status) - directly affects systemic therapy selection and prognostic stratification
- HIPEC (hyperthermic intraperitoneal chemotherapy) - considered at specialized centers when peritoneal metastasis is present alongside ovarian involvement
- MDT (multidisciplinary team) evaluation at a tertiary/HPB or peritoneal malignancy center is strongly recommended
Summary
This clinical scenario represents stage IV CRC with oligometastatic ovarian disease. The prognosis is poor without intervention (median OS ~10-12 months) but substantially better with aggressive cytoreductive surgery + chemotherapy (median OS ~19-30 months). The bilateral nature confers a 66% higher hazard of death compared to unilateral involvement. Achieving R0 resection remains the single most powerful modifiable prognostic determinant. Molecular status (especially KRAS/BRAF) should guide systemic therapy and refine the prognostic estimate.
This is a shared conversation. Sign in to Orris to start your own chat.